Navigation Links
Current Blood Sugar Control Test Results 'Inaccurate'
Date:2/22/2008

Study says measurement underestimates true glucose control in hemodialysis patients

FRIDAY, Feb. 22 (HealthDay News) -- The current standard test for measuring blood sugar control in people with diabetes gives inaccurate results for people on kidney hemodialysis, a U.S. study finds.

Hemodialysis, used to treat patients with kidney failure, involves cleansing blood by circulating it through an artificial kidney machine.

This Wake Forest University Baptist Medical Center study of 307 diabetes patients -- 258 with end-stage kidney disease and 49 who didn't have kidney failure -- found that the HbA1c test underestimated true glucose control in hemodialysis patients. The report is published in the journal Kidney International.

These results suggest that the almost 200,000 diabetic hemodialysis patients in the United States who use this test may not be receiving optimal care for their blood sugar, study senior author Dr. Barry J. Freedman, a professor of internal medicine and nephrology, said in a prepared statement.

Diabetic patients on hemodialysis who believe their blood sugar levels are in the ideal range may actually have unacceptably high blood sugar levels, he noted.

"This was a surprise to the nephrology community. The test we've all come to accept as the gold standard has proven to be inaccurate in this patient population," Freedman said.

He said doctors and patients need to be aware that the HbA1c test underestimates glucose control.

This study was funded by Asahi Kasei Pharma Corp. of Japan, which makes a newer test that measures the amount of blood sugar that's reacted with albumin, a protein in the plasma. The GA (glycated albumin) test is not available in the United States.

More information

The National Kidney Foundation has more about hemodialysis.


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Wild Childs Quit Nits Offers a Safe, Natural Alternative to Current Toxic Head Lice Products
2. American Society for Dermatologic Surgery Supports Current Labeling of Allergans Botox(R) Products
3. Senate Finance Committee Recommends Ways That Medicare Can Enhance Current Physician Quality Reporting Initiative (PQRI)
4. Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation
5. Synutra International, Inc. Amends August 2005 Current Report on Form 8-K and Annual Report on Form 10-K for the Fiscal Year Ended March 31, 2007
6. Physicians Want to Learn From Medical Mistakes But Say Current Error-Reporting Systems are Inadequate
7. Kenneth A. Sylvia Named as New Publisher of Current Psychiatry
8. Quintiles Transnational Forms New Ownership Team with Current Investors Gillings, TPG and Temasek Joined by Bain Capital and 3i
9. ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing
10. Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study
11. Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Current Blood Sugar Control Test  Results 'Inaccurate'
(Date:7/4/2015)... ... 2015 , ... Tyler Boden, Project Developer of Sullivan Solar ... the North American Board of Certified Energy Practitioners (NABCEP®), and is now a ... well established national certification organization for renewable energy professionals. Designation as a NABCEP ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... enrollment on July 2nd creating a buzz of media attention. In an effort ... online by HonestyFirstReviews.com's Tiffany Hendricks. , "These days many people are feeling overwhelmed ...
(Date:7/3/2015)... ... July 03, 2015 , ... Rheumatology ... 2015 Annual Conference , the premiere continuing education and networking event for ... SeaWorld in Orlando, Florida. Speakers include the leading rheumatology experts in immunology, ...
(Date:7/3/2015)... ... 03, 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, ... Rhinoplasty Symposium . To be held from March 4th - 6th, the 2016 (a ... Westin Galleria Dallas. , Designed to take participants from the basic training and fundamentals ...
(Date:7/3/2015)... ... 03, 2015 , ... B. E. Smith, the only full-service ... a national chief nursing officer recruitment for Jane Phillips Medical Center ... industry, B. E. Smith has recently placed more than 1,000 healthcare executives into ...
Breaking Medicine News(10 mins):Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... finds , MONDAY, Dec. 7 (HealthDay News) A new ... in preventing dangerous venous clots as an old standby, warfarin, ... new study finds. , Dabigatran is marketed as Pradax in ... for use in the United States. , The new study, ...
... ... top-of-the-line implementation services to Talyst’s clients in the acute care industry. , ... (PRWEB) December ... the American Society of Health-System Pharmacists in Las Vegas, Talyst announced a partnership ...
... Dec. 7 Hoping to protect their children and grandchildren ... are prepared to make the difficult choices necessary to put ... clear in a report released today by The Concord Coalition ... by a grant from the Peter G. Peterson Foundation, the ...
... , ... 7 Stand Up To Cancer (SU2C) announced today that ... conducted by 13 young scientists. Over a three-year period, each ... part of SU2C,s Innovative Research Grants program, which supports the ...
... , NEW ORLEANS, Dec. 7 Micromet, ... novel, proprietary antibodies for the treatment of cancer, inflammation ... poster(1) with new data from its ongoing phase 1 ... with non-Hodgkin,s lymphoma (NHL) at the 51ST Annual Meeting ...
... , WALTHAM, Mass., Dec. 7 Interleukin Genetics, Inc. ... approval by the State of New York,s Department of Health ... Genetic Test that determines predisposition to severe periodontal disease in ... States in the U.S. However, through its Clinical Laboratory ...
Cached Medicine News:Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:Talyst and RXinnovate Partner on Pharmacy Automation Implementation 2Health News:Concord Coalition Report Shows Eagerness for Reform, Readiness to Make Tough Choices on Fiscal Priorities 2Health News:Concord Coalition Report Shows Eagerness for Reform, Readiness to Make Tough Choices on Fiscal Priorities 3Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 2Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 3Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 4Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 5Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 6Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 7Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 8Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 9Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 2Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 3Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 4Health News:Interleukin Genetics Receives Approval To Sell its PST(R) Periodontal Disease Genetic Test in New York 2Health News:Interleukin Genetics Receives Approval To Sell its PST(R) Periodontal Disease Genetic Test in New York 3
(Date:7/2/2015)... -- According to a new market research report ... Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, Tinnitus, Alzheimer,s, ... by MarketsandMarkets, the global Neuromodulation Market is estimated at $3.65 ... by 2020, at a CAGR of 11.2% during the forecast ... market data T ables and ...
(Date:7/2/2015)... Numotion,s Board of Directors and Mike ... Feitel has joined the Company as Chief Financial ... successful 18 year career at GE serving in executive ... productivity to result in significant industry leading growth and ... Officer for GE Healthcare Global Services, a $5B P&L ...
(Date:7/2/2015)... 25, 2015 ... the addition of the "2015 New ... Challenges, Emerging Technologies, Competitive Landscape" report ... Frontiers in Clinical Chemistry and Immunodiagnostics: Global ... new seven-country strategic analysis of major business ...
Breaking Medicine Technology:Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Numotion Names Tamas Feitel Chief Financial Officer 2New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
... ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 2STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 3STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 4STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 5STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 6STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 7STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 8STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 9STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 10STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 11STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 12STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 13STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 14STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 15STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 16STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 17Orexigen(R) Therapeutics Schedules March 9, 2010 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2009 2Orexigen(R) Therapeutics Schedules March 9, 2010 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2009 3
... 200 to 350 Liters of pure water, ... Distribution of Purified Water,Millipores compact S.D.S. Storage ... 200 to 350 liters of purified water ... to maintain consistent purity of stored water, ...
... 200 to 350 Liters of pure water, ... Distribution of Purified Water,Millipores compact S.D.S. Storage ... 200 to 350 liters of purified water ... to maintain consistent purity of stored water, ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
Medicine Products: